Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05572333
Other study ID # EP395-003
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 22, 2022
Est. completion date November 24, 2023

Study information

Verified date November 2023
Source EpiEndo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.


Description:

This is a randomised, double-blind, placebo-controlled, multicentre study to assess the safety and tolerability of EP395 in COPD patients. In this study, EP395 will be administered to COPD patients for the first time. Patients will receive either EP395 or placebo as oral capsules once-daily for 12 weeks. Safety and tolerability will be assessed, as well as effect on lung function, lung inflammation and systemic inflammation. Patients' symptoms and quality of life will be assessed with questionnaires. In a sub-set of patients, bronchoscopies will be conducted, to investigate exploratory biomarkers in bronchial brushings and bronchoalveolar lavage.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date November 24, 2023
Est. primary completion date November 24, 2023
Accepts healthy volunteers No
Gender All
Age group 45 Years and older
Eligibility Inclusion Criteria: 1. Willing and able to understand the information on the nature, the scope, and the relevance of the study, and to provide voluntary, written informed consent to participate in the study before any study-related procedures 2. Men and women, aged =45 years 3. Women of childbearing potential must: 1. have a negative pregnancy test (blood) at Screening and (urine) Day 1 2. agree to use, and be able to comply with, highly effective measures of contraceptive control (failure rate less than 1% per year when used consistently and correctly) without interruption, during study participation and until 90 days after the last investigational product (IP) intake. 3. agree to abstain from breast feeding during the study participation and for 90 days after the last IP intake. 4. Men must agree to use a condom during sexual intercourse with women of childbearing potential during treatment and for 90 days after the last IP intake and should not donate sperm during this time 5. Diagnosed with COPD for at least 2 years with FEV1/forced vital capacity (FVC) ratio <0.70 and FEV1 <70% (post bronchodilator) at Screening 6. Receiving at least one maintenance inhaled therapy (ie, long acting beta-agonist [LABA], long acting muscarinic antagonist [LAMA], LABA/LAMA, LABA/inhaled corticosteroid [ICS], LAMA/ICS, or LABA/LAMA/ICS) for at least 3 months before Screening 7. Able to tolerate the sputum induction procedure and to produce an adequate (volume and sufficient quality for cell count) sputum sample 8. Body mass index of =19 and =35 kg/m2 9. History of sputum production (bronchitic phenotype) for approximately 3 months (minimum, not consecutive) in a year 10. Up to date COVID-19 vaccination (according to local law and guidelines) Exclusion Criteria: 1. History or presence of any clinically relevant medical condition including laboratory test abnormality or planned surgery that in the investigator's opinion could affect the patient's safety or interfere with the objectives of the study 2. Exacerbation of COPD in the 3 months before Screening 3. Change in medication for COPD in the 3 months before Screening 4. Lung function at Screening that in the investigator's opinion would indicate not safe to perform sputum induction or bronchoscopy (bronchoscopy applicable only in a subset of patients) 5. History of or active tuberculosis 6. Malignancy within the past 5 years, except removed basal cell carcinoma and resected benign colonic polyps 7. Clinically significant abnormality on 12-lead ECG including prolonged corrected QT interval by Fredericia (QTcF) (>450 msec in men or >470 msec in women; based on triplicate) at Screening and Day 1 pre-dose 8. Absolute estimated glomerular filtration rate ([eGFR cystatin C + eGFR creatinine]/2) <60mL/min according to Lund-Malmö equation at Screening 9. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 x upper limit of normal at Screening 10. Use (including prescription, over-the-counter, herbal or dietary) of cytochrome P450 (CYP) inducers within 28 days before first dosing, or strong or moderate inhibitors of CYP3A4 (including dietary eg, grapefruit juice) or P-glycoprotein (Pgp) inhibitors or oral narrow therapeutic index (TI) Pgp substrates (eg, digoxin) within 14 days before first dosing (substrates, inhibitors, and inducers are listed in https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interac tions-table-substrates-inhibitors-and-inducers) 11. Use of macrolide, roflumilast, or oral corticosteroid (OCS) within 28 days before Screening 12. Ongoing antibiotic treatment at Screening 13. Use of home oxygen or home-based non-invasive ventilation 3 months before Screening 14. Use of a biological therapy within 3 months before Screening 15. Use of herbal remedies within 28 days before first dose until follow-up 16. Live vaccine within 28 days or any other vaccine within 14 days before first dose until 28 days after final dose of the IP (with the exception of COVID-19 booster and flu vaccination; see Previous and concomitant medications and therapies) 17. Positive hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus 1 or 2 antibodies at Screening 18. Positive test result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on Day 1 19. Positive drugs of abuse test at Screening, including cotinine only in ex-smokers for at least 3 months 20. Use of e-cigarettes and vapes 21. History of alcohol or drug misuse within 12 months before Screening 22. Pregnant and lactating women 23. Prior recovery from recent infection, including but not limited to COVID 19 within the last 30 days before first dosing with IP 24. Known hypersensitivity to macrolides or EP395 or any of the excipients (dicalcium phosphate, croscarmellose sodium, magnesium stearate, microcrystalline cellulose) 25. Participation in a study of an experimental drug within 5 half-lives or 3 months before Screening, whichever is longer 26. Dependent subjects of the sponsor or investigator (eg, employees, relatives) 27. Patients without the capacity to understand the nature and risks of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EP395
Capsule for oral use
Placebo
Capsule for oral use

Locations

Country Name City State
Germany IKF Pneumologie GmbH & Co. KG Frankfurt
Germany Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH Großhansdorf
Germany IKF Pneumologie GmbH & Co. KG Institut für klinische Forschung Pneumologie Mainz
United Kingdom Bradford Royal Infirmary, Clinical Research Facility Bradford
United Kingdom Medicines Evaluation Unit Ltd. (MEU) Manchester
United Kingdom Southampton University Faculty of Medicine Southampton

Sponsors (2)

Lead Sponsor Collaborator
EpiEndo Pharmaceuticals FGK Clinical Research GmbH

Countries where clinical trial is conducted

Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of adverse event (AE) occurrence From Screening (Day -28 to Day -1) to Day 100
Primary Vital signs: Systolic and diastolic blood pressure Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Vital signs: Pulse Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Vital signs: Body temperature Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Vital signs: Respiratory rate Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Assessment of laboratory values (haematology) Mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, mean corpuscular volume, haematocrit, haemoglobin, platelet count, white blood cell count with differentials (neutrophils, lymphocytes, monocytes, eosinophils, basophils).
Absolute values and changes from baseline will be summarized for all assessed time points.
Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Assessment of blood coagulation International normalized ratio, prothrombin time (quick test), and activated partial thromboplastin time will be assessed.
Absolute values and changes from baseline will be summarized for all assessed time points.
Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Assessment of laboratory values (biochemistry) Liver function parameters and fasting lipids (at Screening and Day 84) will be assessed in addition to the following other parameters: bicarbonate, calcium, creatinine, creatine phosphokinase, cystatin C (screening only), fasting glucose (at Screening only), sodium, urea, estimated glomerular filtration rate (at Screening only)
Absolute values and changes from baseline will be summarized for all assessed time points
Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 100
Primary Urinalysis pH, glucose, protein, blood (hemoglobin), leukocytes, ketones and nitrite will be assessed.
Clinical abnormalities will be evaluated
Screening (Day -28 to Day -1), Day 1, Day 28, Day 56, Day 84, Day 100
Primary ECG heart rate Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary ECG RR interval Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary ECG PR interval Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary ECG QRS duration Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary ECG QT interval (uncorrected) Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary ECG QTcF intervals Absolute values and changes from baseline will be summarized for all assessed time points Screening (Day -28 to Day -1), Day 1, Day 14, Day 28, Day 56, Day 84, Day 100
Primary Standard routine physical examination A standard routine physical body examination will be performed and abnormal physical examination results will be evaluated. Clinically significant abnormalities will be reported as AEs. Screening (Day -28 to Day -1), Day 1, Day 28, Day 56, Day 84, Day 100
Secondary Sputum cells (total and differential) and inflammatory mediators Assessment of inflammatory mediators will include mediators including interleukin (IL) 8, tumour necrosis factor (TNF)-a, IL-6, IL 1ß, macrophage inflammatory protein (MIP) 1a, MIP-1ß, monocyte chemotactic protein (MCP)-1, surfactant protein D (SP-D), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-23, IL-33, IL-25, IL-10, neutrophil elastase (NE), matrix metalloproteinase (MMP)-9, CXC motif chemokine ligand (CXCL)1, myeloperoxidase (MPO) Screening (Day -28 to Day -1), Day 1, Day 42, Day 70, Day 84
Secondary Blood inflammatory markers Including assessment of fibrinogen (FBG), C-reactive protein (CRP), TNF-a, IL-6 and a2 macroglobulin Day 1, Day 42, Day 84
Secondary Forced expiratory volume in 1 second (FEV1) Screening (Day -28 to Day -1), Day 1, Day 28, Day 56, Day 84
Secondary Plasma levels of EP395 Day 14, Day 28, Day 42, Day 56, Day 70, Day 80, Day 84
Secondary St George's respiratory questionnaire (SGRQ) Screening (Day -28 to Day -1), Day 1, Day 28, Day 56, Day 84
Secondary Exacerbations of COPD tool (EXACT) respiratory symptoms (E-RS) Screening (Day -28 to Day -1), daily from Day 1 to Day 84
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy